Cascade Pharmaceuticals, Inc
Clinical trials sponsored by Cascade Pharmaceuticals, Inc, explained in plain language.
-
New hope for rare liver disease: phase 3 trial of CS0159 launches
Disease control Recruiting nowThis study tests a new drug called CS0159 in 135 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants must have had an inadequate response or intolerance to the standard treatment UDCA. The trial compares CS0159 to a placebo over 52 weeks to see if…
Phase: PHASE3 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill aims to melt liver fat in NASH patients
Disease control Recruiting nowThis study tests a new tablet called CS060380 for adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 120 participants will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track a…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC